Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Aadi Bioscience Inc (NASDAQ:AADI) shares are trading lower after the company released results from a planned interim analysis on the first third of participants in the ongoing tumor-agnostic PRECISION1 trial of nab-sirolimus in patients with TSC1 or TSC2 inactivating alterations.
The interim analysis includes data from the first third of trial participants (n=40) with a minimum of 4.5 months of follow-up, including investigator-assessed response and safety analyzed separately in each TSC1 and TSC2 arms.
Efficacy of nab-sirolimus in patients with tumors harboring pathogenic inactivating alteration in TSC1
Efficacy of nab-sirolimus in patients with tumors harboring pathogenic inactivating alteration in TSC2
No new safety signals were observed, and no grade-four treatment-related events or deaths occurred.
Eighty patients are enrolled in the PRECISION1 trial, supporting the two-thirds interim analysis expected in Q3 of 2024. The ORR analysis in this cohort will be based on an independent radiological review with at least six months of follow-up for all patients.
The trial is expected to be completed by the end of 2024, with results anticipated in early 2025.
Price Action: AADI shares are down 56.24% at $2.35 during the premarket session on the last check Friday.
Posted In: AADI